drugset / Trial / NCT00819052

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

NCT00819052

Phase 3 Completed 445 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to demonstrate the efficacy of nevirapine extended release (NVP XR) based regimen for HIV-1 infected patients who were receiving nevirapine immediate release (NVP IR) based regimen for at least 18 prior weeks of therapy.

Timeline

Start
2008-12
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nevirapine Small molecule 200 mg Oral
Subject Nevirapine Small molecule 400 mg Oral